PRostate Evaluation for Clinically Important Disease: Sampling Using Image-guidance Or Not?

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2016
This evaluates the detection rates of prostate cancer by MRI-targeted prostate biopsy compared to standard 12-core trans-rectal ultrasound guided (TRUS) prostate biopsy. Each participant will be randomly allocated to one of the biopsy tests. We hypothesise that MRI-targeted biopsy will detect no fewer clinically significant cancers than TRUS biopsy but will detect fewer clinically insignificant prostate cancers than TRUS biopsy.
Epistemonikos ID: c5ae1c0ded2121bfb6aa592442a053615aff886d
First added on: May 12, 2024